picropodophyllin has been researched along with Carcinoma, Non-Small Cell Lung in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M | 1 |
| Abrahmsen, L; Alvfors, C; Axelson, M; Bergqvist, M; Bergström, S; Ekman, S; Eksborg, S; Frödin, JE; Harmenberg, J; Hedlund, Å; Jerling, M; Larsson, O; Ståhl, B; Wassberg, C | 1 |
| Andor, G; Bergqvist, M; Bondarenko, I; Grechanaya, E; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Maximovich, A; Thureson, M | 1 |
3 trial(s) available for picropodophyllin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Podophyllotoxin; Prognosis; Receptor, IGF Type 1; Tissue Distribution | 2015 |
A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Neutropenia; Podophyllotoxin; Prospective Studies; Receptor, IGF Type 1; Signal Transduction; Treatment Outcome | 2016 |
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2017 |